PharmaCyte Biotech Moves Closer to Filing IND with Naming

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
27
PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity

LAGUNA HILLS, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today discussed the comparator arm for its upcoming clinical trial and provided additional clarification on its recent pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding its upcoming clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

In the company’s upcoming trial, the comparator arm that PharmaCyte’s pancreatic cancer therapy will be compared to is the combination of the cancer drug 5-fluorouracil (FU) and the compound leucovorin (LV). The necessary and quick decision was made by Dr. Manuel Hidalgo, the Principal Investigator for the upcoming clinical, Dr. Daniel Von Hoff with Translational Drug Development (TD2), the CRO for PharmaCyte’s clinical trial, and Dr. Matthias Löhr, the Chairman of PharmaCyte’s Medical and Scientific Advisory Board.

“After our pre-IND meeting I am more confident and enthusiastic than ever about PharmaCyte’s ability to validate its therapy for locally advanced, inoperable pancreatic cancer in a human clinical trial,” stated PharmaCyte’s Chief Executive Officer, Kenneth L Waggoner. 

He continued, “And I am quite gratified that the FDA sees enough potential in our product to consider our trial a pivotal one under the right circumstances. Now the mission for our entire team is to work diligently towards the submission of our IND to the FDA. We all feel that the suggested changes we received from the FDA should not take long to make and will certainly be well worth it in the long run. For example, we quickly gained agreement on the comparator arm for the trial and, in doing so, we’ve moved closer to filing our IND with the FDA.”

PharmaCyte’s management, Dr. Manuel Hidalgo, TD2 and TD2’s consulting statistician are actively working to finalize the number of patients that will be included in the trial. This is the final element and will complete the adjustments necessary for a newly designed trial.

In PharmaCyte’s recent pre-IND meeting with the FDA, the FDA stated that it would be willing to change PharmaCyte’s clinical trial from an “exploratory” trial to a “pivotal” trial under certain conditions. A pivotal trial is a clinical trial intended to provide evidence for a drug marketing approval by the FDA.

This indeed is a landmark moment in PharmaCyte’s history. Generally, a pivotal trial must be a Phase 3 trial (which PharmaCyte’s upcoming trial could be labeled); in such a trial several hundred patients can be treated.  However, the FDA indicated that: (i) if PharmaCyte’s therapy shows real promise; (ii) includes a sufficient number of patients; and (iii) includes primary endpoints of overall survival (OS) and safety rather than progression free survival (PFS) and safety, the trial may be considered a pivotal trial.  

Mr. Waggoner said of this opportunity, “This is good news for PharmaCyte shareholders since the change from an “exploratory” trial to a “pivotal” trial can eliminate one or two lengthy and costly trials and potentially make PharmaCyte’s Cell-in-a-Box ® -based product, CypCaps™, “market-ready” in a much shorter period of time than anticipated. It may also accelerate the overall development timeline if the results are very positive, thus making the therapy more attractive to potential investors or suitors.”

To be a pivotal trial, the FDA wants at least 100 patients treated with CypCaps™ for purposes of determining the safety of PharmaCyte’s therapy. In the trial’s original design only 40 or so patients would have received CypCaps™ and been evaluated for safety.

Other highly positive news provided by Mr. Waggoner concerning the pre-IND meeting with the FDA included:

  • agreement with the FDA that PharmaCyte is on the “right track” in its development program;
  • agreement with the FDA on the cell line that will be used in the clinical trial;
  • agreement with the FDA on the patient population to be studied in the clinical trial;
  • agreement with the FDA on the secondary endpoints of the clinical trial, except that PFS will be added to the list of secondary endpoints if the trial becomes a pivotal trial;
  • agreement with the FDA on the number of patients needed to comprise an adequate safety database for a Biologics Licensing Application for CypCaps™;
  • agreement that the FDA believes CypCaps™ is a drug/device combination product;
  • agreement with the FDA that it will assist PharmaCyte in its development program; and
  • agreement with the FDA that the next step for PharmaCyte is to submit an IND.

There is still a “hard stop” at the six-month mark after a certain number of patients have been enrolled in the trial to review the data generated to that point. The timing of this hard stop may change, however, to the point in time when 50% of the patients have been treated. Because the clinical trial is an “open-label” trial (the trial is not a “blinded” study), this interim analysis should give PharmaCyte an important indication of the successfulness of its CypCaps ™ therapy for LAPC.

Mr. Waggoner commented on the significance of following the FDA’s guidance moving forward stating, “We have one shot at this, and we intend to get it right. We greatly appreciate the continued patience and support of our shareholders during this process.”

About PharmaCyte Biotech PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box ® .” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.

In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box ® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte can be found at www.PharmaCyte.com . It can also be obtained by contacting Investor Relations.

Investor Relations: PharmaCyte Biotech, Inc. Investor Relations Department Telephone: 917.595.2856 Email: Info@PharmaCyte.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 222

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 64

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 202

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 86

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 41

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 177

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 94

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Labcorp's Brazil Trial Push Has Promise and Plenty to Prove

Updated Category News Views 93

Brazilian clinical-trial kit deliveries may soon spend less time tangled in international shipping. That is the practical heart of Labcorp's newly announced collaboration with Grupo Fleury, and frankly, practical is plenty good in this business. Labcorp plans to begin assembling clinical-trial kits locally in Brazil in early 2027, then add laboratory operations by the end...

Continue Reading

Top 5 Most Recently Viewed Articles

Hormel Foods Welcomes Debbra Schoneman to Board of Directors

Updated Category News Views 77

Debbra Schoneman Joins Hormel Foods Board of Directors Hormel Foods Corporation (NYSE: HRL), a leader in the global branded food sector, is excited to announce the election of Debbra Schoneman to its Board of Directors. This pivotal decision aligns with the company's ongoing dedication to excellence and innovative leadership. Debbra Schoneman's Background Jim Snee, the...

Continue Reading
Superorganism Secures $25.9M for Biodiversity Ventures

Updated Category News Views 182

Superorganism Secures $25.9M for Biodiversity Ventures Nature and technology fund backed by leading investors aims to redefine how capital advances biodiversity Superorganism, a pioneering venture capital firm focusing on technology solutions for biodiversity, recently announced the successful closure of its debut fund, garnering commitments amounting to $25.9 million....

Continue Reading
Teamsters Local 838 Welcomes First Student Workers in Missouri

Updated Category News Views 174

Teamsters Local 838 Welcomes First Student Workers In a significant development for school transportation workers, more than 100 bus drivers and monitors at First Student in Missouri have united under Teamsters Local 838. This successful vote marks a substantial step in expanding Teamster representation within the school transportation sector, ensuring these workers have...

Continue Reading
Exploring Promising Tech Innovators: Beyond the Giants

Updated Category News Views 121

Understanding the Tech Landscape The technology sector has captured the spotlight as one of the leading areas of growth in recent times. Yet, within this vast landscape, not all players enjoy the same level of success. Many people automatically think of established giants when they hear "tech"—companies often dubbed as the Magnificent Seven, including major players such...

Continue Reading
Highland Copper Innovates with New Drilling and Flotation Tech

Updated Category News Views 112

Highland Copper's New Drilling Program for Metallurgy Highland Copper Company Inc. is taking an exciting step forward with a new drilling program aimed at exploring and optimizing its mining operations. This initiative demonstrates Highland Copper's dedication to utilizing innovative and sustainable mining methods, significantly enhancing its project economics. Focusing...

Continue Reading